Urinary tract infections (UTIs) represent one of the most common bacterial infections of humans. Recurrence and persistence of UTIs, in spite of appropriate antibiotic therapry, has been attributed, at least in part, to the pathogen seeking intracellular refuge within bladder cells. Type 1 fimbriated uropathogenic E.coli (UPEC) accounts for over 80% of all UTIs. The virulence of the bacteria is associated with its capacity to invade the superficial bladder epithelium and avoid elimination in the urine. We have recently discovered that during infection in an experimental model of UTI, UPEC were entering and harboring within fusiform vesicles of superficial epithelial cells of the bladder. Remarkably, artificially boosting intracellular levels of cAMP in BECs induced bacterial expulsion from infected BECs, and also impeded bacterial invasion of BECs. Conceivably, use of artificial enhancers of cAMP to reduce entry and to expel bacteria from intracellular niches could be of therapeutic value. In pilot experiments, we have successfully eliminated bacteriurea in UPEC infected mice following intraperitoneal instillation of forskolin, a cAMP booster. Forskolin (a derivative of the plant herb Coleus forskohlii) is unlikely to be toxic to humans considering that Coleus forskohlii extracts have been employed for medicinal purposes for centuries in Asia. In the US, use of forskolin for a variety of ailments is rapidly increasing as interest in alternative medicine has grown.
The specific aims are to: (i) Employ an ex vivo model of bladder infection, to demonstrate (a), the dependence of UPEC on intracellular cAMP levels during invasion of BECs and (b), the ability to manipulate bacterial burden in infected BECs with modulators of cAMP. (ii) Elucidate the molecular events leading to how intracellular cAMP negatively modulates UPEC invasion into BECs and how artificially increasing cAMP levels triggers bacterial expulsion.(iii) Examine the efficacy of forskolin treatment as an alternative or complement to antibiotic therapy for UTIs. The proposed studies should provide valuable information on the role of cAMP as a potent modulator of bacterial invasion and expulsion from BECs. ? ? ?
|St John, Ashley L; Ang, W X Gladys; Rathore, Abhay P S et al. (2018) Reprograming immunity to food allergens. J Allergy Clin Immunol 141:1936-1939.e2|
|Miao, Yuxuan; Bist, Pradeep; Wu, Jianxuan et al. (2017) Collaboration between Distinct Rab Small GTPase Trafficking Circuits Mediates Bacterial Clearance from the Bladder Epithelium. Cell Host Microbe 22:330-342.e4|
|Hsia, Bethany J; Ledford, Julie G; Potts-Kant, Erin N et al. (2016) Correction notice for TNF-R on mast cells regulate airway responses to Mycoplasma pneumoniae. J Allergy Clin Immunol 137:336|
|Karhausen, Jörn; Abraham, Soman N (2016) How mast cells make decisions. J Clin Invest 126:3735-3738|
|Choi, Hae Woong; Abraham, Soman N (2016) Why Serological Responses during Cystitis are Limited. Pathogens 5:|
|Miao, Yuxuan; Wu, Jianxuan; Abraham, Soman N (2016) Ubiquitination of Innate Immune Regulator TRAF3 Orchestrates Expulsion of Intracellular Bacteria by Exocyst Complex. Immunity 45:94-105|
|Abraham, Soman N; Miao, Yuxuan (2015) The nature of immune responses to urinary tract infections. Nat Rev Immunol 15:655-63|
|Miao, Yuxuan; Li, Guojie; Zhang, Xiaoli et al. (2015) A TRP Channel Senses Lysosome Neutralization by Pathogens to Trigger Their Expulsion. Cell 161:1306-19|
|Miao, Yuxuan; Abraham, Soman N (2014) Peeing pentraxins. Immunity 40:460-2|
|St John, Ashley L; Ang, W X Gladys; Huang, Min-Nung et al. (2014) S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection. Immunity 41:440-450|
Showing the most recent 10 out of 33 publications